Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Pediatric Oncology
•
ALL
What is your first choice TKI for pediatric patients with Ph+ ALL who are not on a study?
Answer from: at Academic Institution
The first choice for TKI in children/adolescents with Ph+ ALL should be dasatinib based on a recent study published in JAMA Oncology (Shen et al).
Sign in or Register to read more
7488
Related Questions
How do you incorporate blinatumomab into therapy for a pediatric or AYA patient with isolated CNS relapse of B-ALL, if at all?
For a pediatric patient with B-ALL who requires surgery during maintenance, what therapy modifications do you recommend to allow for optimal healing and minimal treatment disruption?
How would you manage an early isolated CNS relapse in a pediatric patient with Ph positive ALL?
Do you check asparaginase levels for all patients receiving receiving E. coli-derived products, or only in certain clinical situations?
How do you address logistic barriers related to blinatumomab when treating relapsed B-ALL?
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
Does the presence of asparaginase antibodies on Granger Genetics testing indicate need to switch asparaginase formulations?
How do you manage severe hypertriglyceridemia in the adolescent & young adult population receiving chemotherapy for ALL, in the absence of complications related to hypertriglyceridemia?
What is your practice regarding giving G-CSF to patients with ALL during initial induction?
Would you consider post-BMT maintenance therapy for patients with Ph-like ALL with a JAK2 mutation?